|1.||Kahle, Kristopher T: 9 articles (06/2008 - 01/2003)|
|2.||Lifton, Richard P: 9 articles (06/2008 - 01/2003)|
|3.||Shaw, Reuben J: 8 articles (08/2014 - 03/2004)|
|4.||Friedman, Eileen: 7 articles (07/2011 - 12/2003)|
|5.||Sen, Subrata: 7 articles (04/2011 - 03/2003)|
|6.||Marais, Richard: 6 articles (03/2013 - 06/2002)|
|7.||Lahn, Michael: 6 articles (06/2011 - 08/2007)|
|8.||Hebert, Steven C: 6 articles (06/2008 - 01/2003)|
|9.||Mukaida, Naofumi: 5 articles (12/2015 - 03/2005)|
|10.||Yu, Long: 5 articles (02/2015 - 06/2007)|
12/01/2013 - "Previous studies have identified gene rearrangements in the microtubule-associated serine-threonine kinase (MAST) and NOTCH gene families in 5% to 7% of invasive breast cancers. "
10/01/2012 - "After reviewing this basic information, we will examine newer studies that demonstrate the pathophysiological consequences to SPAK and/or OSR1 disruption, discuss the development and analysis of genetically engineered mouse models, and address the possible role these serine/threonine kinases might have in cancer proliferation and migration."
02/01/2005 - "Recent studies indicate that dysregulation of the Akt/PKB family of serine/threonine kinases is a prominent feature of many human cancers. "
11/01/1997 - "All of the mutations in the present study occurred within the highly conserved serine/threonine kinase domain and represent the first report of such 'direct' TbetaR-II mutations in primary human tumors. "
11/01/2015 - "The serine/threonine kinase LKB1 is a well-characterized tumor suppressor that governs diverse cellular processes, including growth, polarity, and metabolism. "
04/09/1999 - "The current study investigated serine kinase activity toward IRS-1 in several models of insulin resistance. "
12/01/2012 - "These results indicate that activation of the serine kinase JNK contributes, at least in part, to oxidative stress-induced insulin resistance in isolated mammalian skeletal muscle."
03/06/2009 - "The serine/threonine kinase Akt is a focal point in signaling pathways that control cell tumorigenesis and insulin resistance. "
09/01/2002 - "Reversal of the impaired IR signaling by inhibitors of serine kinase activity suggests that serine kinase-mediated pathways may be involved in the insulin resistance. "
04/09/1999 - "Identification of enhanced serine kinase activity in insulin resistance."
|3.||Melanoma (Melanoma, Malignant)
08/01/2009 - "Mutational profiling studies have shown that the majority of melanomas harbor activating mutations in the serine/threonine kinase BRAF at the V600E position. "
08/01/2015 - "The results suggest that serine/threonine kinases may be viable therapeutic targets for the treatment of canine malignant melanoma."
01/01/2015 - "Mutations in the serine/threonine kinase BRAF are found in more than 60% of melanomas. "
01/01/2015 - "MAP3K7 (known as TAK1), a serine/threonine kinase along the MAPK signaling pathway, was over-expressed in melanoma but decreased following ectopic expression of miR-377. "
04/01/2014 - "Vemurafenib is a small molecule inhibitor of the BRAF serine-threonine kinase recently approved by the United States Food and Drug Administration to treat patients with metastatic and unresectable melanomas that carry an activating BRAF (V600E) mutation. "
01/08/2015 - "IRAK4, a serine/threonine kinase, plays a key role in both inflammation and oncology diseases. "
05/15/2012 - "Thus, the double-edged sword effect of inhibition of NF-κB via inhibition of both serine/threonine kinase and PTK by biochanin might show useful therapeutic value against activities of cells that lead to tumorigenesis and inflammation."
04/13/2012 - "Bcr is a serine/threonine kinase that is a critical regulator of vascular smooth muscle cell inflammation and proliferation. "
04/01/2010 - "The molecular mechanisms that contribute to this inflammation are still somewhat unclear, but several serine/threonine kinases are known to be involved. "
05/01/2002 - "Recent studies have implicated fatty acid-dependent activation of the serine kinase IKKbeta, which plays a key role in tissue inflammation, in the pathogenesis of insulin resistance. "
|5.||Hematologic Neoplasms (Hematological Malignancy)
01/01/2015 - "The Pims are a small family of serine/threonine kinases with increased expression across the hematological malignancies. "
12/01/2012 - "Pim1 is a unique, constitutively active serine/threonine kinase, and is a potent oncogene overexpressed in a range of hematologic malignancies and solid cancers. "
06/01/2010 - "PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers."
11/12/2009 - "Pim-1, Pim-2, and Pim-3 are a family of serine/threonine kinases which have been found to be overexpressed in a variety of hematopoietic malignancies and solid tumors. "
06/01/2010 - "Here, we summarize the current knowledge about the role of PIM serine/threonine kinases for the pathogenesis and therapy of hematologic malignancies and solid cancers, and we highlight structural principles and recent progress on small molecule PIM kinase inhibitors that are on their way into first clinical trials."
|2.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|3.||6-pyruvoyltetrahydropterin synthase (PTPS)
|6.||Protein Kinases (Protein Kinase)
|8.||Proto-Oncogene Proteins c-akt (Protein Kinase B)
|9.||Glycogen Synthase (Synthase I)
|10.||Transforming Growth Factor beta (TGF-beta)
|4.||Drug Therapy (Chemotherapy)